Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Deloitte
Fuji
Federal Trade Commission
Harvard Business School
Boehringer Ingelheim
Citi
Baxter
QuintilesIMS
Novartis

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021342

« Back to Dashboard

NDA 021342 describes LEVO-T, which is a drug marketed by Alara Pharm and is included in one NDA. It is available from sixteen suppliers. There is one patent protecting this drug. Additional details are available on the LEVO-T profile page.

The generic ingredient in LEVO-T is levothyroxine sodium. There are ten drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the levothyroxine sodium profile page.

Summary for 021342

Tradename:1
Applicant:1
Ingredient:1
Patents:1
Therapeutic Class:Hormonal Agents, Stimulant/Replacement/Modifying (Thyroid)
Formulation / Manufacturing:see details

Pharmacology for NDA: 021342

Ingredient-typeThyroxine

Suppliers and Packaging for NDA: 021342

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LEVO-T levothyroxine sodium TABLET;ORAL 021342 NDA AUTHORIZED GENERIC Sandoz Inc. 0781-5180 0781-5180-92 90 TABLET in 1 BOTTLE (0781-5180-92)
LEVO-T levothyroxine sodium TABLET;ORAL 021342 NDA AUTHORIZED GENERIC Sandoz Inc. 0781-5180 0781-5180-01 100 TABLET in 1 BOTTLE (0781-5180-01)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Approval Date:Mar 1, 2002TE:AB1,AB2,AB3RLD:Yes
Patent:► SubscribePatent Expiration:Mar 30, 2020Product Flag?Substance Flag?Delist Request?

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Approval Date:Mar 1, 2002TE:AB1,AB2,AB3RLD:Yes
Patent:► SubscribePatent Expiration:Mar 30, 2020Product Flag?Substance Flag?Delist Request?

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Approval Date:Mar 1, 2002TE:AB1,AB2,AB3RLD:Yes
Patent:► SubscribePatent Expiration:Mar 30, 2020Product Flag?Substance Flag?Delist Request?


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Moodys
US Army
Mallinckrodt
Cerilliant
Cipla
Cantor Fitzgerald
Express Scripts
Johnson and Johnson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot